BioCardia Regained Nasdaq Compliance After Price Drop
The company met minimum bid price requirements after shares struggled in recent trading sessions.
Updated on Sept. 22, 2026 in Public Companies

Live Poll
Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?
BioCardia has regained compliance with the Nasdaq minimum bid price requirement after maintaining a closing price of at least $1 for 10 consecutive business days. The announcement follows a period where the company previously fell out of compliance.
Why it matters
Maintaining Nasdaq compliance is essential for companies to avoid delisting, which can significantly impact liquidity and investor confidence. BioCardia remains cautious, noting no assurance that it will successfully maintain the $1 threshold in the future.
BioCardia shares closed at $1.08 in the regular session before falling 10.19 percent to $0.97 in after-hours trading. The company currently holds a market capitalization of approximately $16.35 million.
The players
BioCardia
This is a medical technology company that develops regenerative medicine and cardiovascular therapies.
Nasdaq
This is a global electronic marketplace for securities trading that enforces listing requirements for public companies.
The details
The firm faced regulatory scrutiny in August 2026 after trading below the $1 threshold for 30 consecutive business days. Despite regaining compliance, the stock has seen a 2.7 percent decline over the past 12 months, with 52-week extremes ranging from $0.75 to $1.80.
Timeline
August 2026: BioCardia received the initial Nasdaq non-compliance notice.
September 21, 2026: BioCardia shares traded in the regular session.
September 21, 2026: Shares fell 10.19 percent during after-hours trading.
Market Landscape
This development reflects the ongoing pressure on small-cap firms to meet exchange listing standards to prevent potential delisting. Such compliance hurdles highlight the broader challenges companies with a market capitalization under $20 million face in maintaining investor interest.
Investors should note that while compliance is restored, the volatility of the stock price remains a factor for shareholder equity. The recent after-hours decline suggests continued market sensitivity regarding the company's valuation.
The takeaway
Maintaining listing requirements is a mandatory hurdle for small-cap stocks to avoid the liquidity risks associated with delisting. Investors should monitor future trading sessions closely to see if the company can sustain its current price level above the exchange-mandated minimum.
Further reading
For more information on market regulatory standards, visit the Public Companies section.
Live Poll
Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?






